We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.51 | -0.40% | 127.00 | 127.73 | 126.76 | 127.32 | 6,551,963 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Merck & Co. (MRK) on Thursday said Health Canada approved its cancer drug Keytruda in combination with Pfizer Inc.'s (PFE) Inlyta for the first-line treatment of patients with advanced renal cell carcinoma, the most common type of kidney cancer.
The Kenilworth, N.J., drug maker said the approval is based on a phase 3 study that showed significant improvements in overall survival, progression-free survival and objective response rate for the combination compared with sunitinib.
Keytruda, which was first approved in Canada in 2015, currently has 14 indications in several disease areas in the country, Merck said.
Merck last year received U.S. and European Union approval for the Keytruda/Inlyta combination in advanced renal cell carcinoma.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 23, 2020 08:06 ET (13:06 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
